Kairos Pharma, LTD.
Kairos Pharma, Ltd. is a U.S.-based clinical-stage pharmaceutical company focused on acquiring, licensing, and developing drug candidates and related intellectual property. The company has no approved products or product sales yet, and its current business is centered on preclinical and clinical development, IP portfolio building, and capital raising to fund operations.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueExclusive license rights to patented technologies and drug-development programs sourced from Cedars.
Early-stage research, candidate selection, and nonclinical studies to advance product concepts.
Human clinical studies and related regulatory preparation for product candidates.
Patent portfolio management, licensing, and partnering activities that support commercialization.
Customers
Kairos Pharma does not yet sell approved products, so its near-term counterparties are not traditional end customers but rather licensors, advisors, investors, and potential development partners. If its programs advance, the eventual buyers would be hospitals, physicians, and patients through pharmaceutical commercialization channels, but today the company is primarily funded by equity investors and supported by consulting and advisory relationships.
Provide capital through IPO, PIPE, ELOC, and private financings because the company has no product revenue.
Supply exclusive patent rights and know-how, including Cedars-licensed programs that underpin the pipeline.
Support corporate strategy, investor relations, valuation, and financing execution.
May license or co-develop programs to help fund development and future commercialization.
Hospitals, physicians, and patients would be the ultimate users if candidates are approved.
Strategy
Kairos Pharma’s strategy is to advance licensed therapeutic programs through preclinical and clinical development while building the intellectual property base needed for eventual partnering or commercialization. Near term, the company is prioritizing financing execution, advisory support, and public-company infrastructure so it can continue development without product revenue.
Clinical progress is the main value driver for a company with no product sales.
The company needs external capital to fund operations until any product revenue exists.
Collaborations can provide cash, validation, and commercialization reach without full internal buildout.
Investor communications and corporate strategy support access to capital and deal flow.
Geography
Kairos Pharma is headquartered in the United States and its current operating footprint is primarily U.S.-based, reflecting a domestic clinical-stage biotech model. The company also uses non-U.S. counterparties for advisory and financing support, including Canadian and Puerto Rico-based service providers, but it has not disclosed meaningful country-level revenue because it has not generated product sales.
Risks
Kairos Pharma is exposed to the core risks of a clinical-stage biotech: it may never obtain regulatory approval, may fail to raise enough capital, and may need to dilute shareholders to fund operations. Because it has no product revenue, execution risk in development and financing is especially important, and any setback can materially affect the company’s ability to continue as a going concern.
The company has no sales and must finance development through equity, debt, or partnerships.
Drug candidates may not demonstrate safety or efficacy, or may not obtain approval.
Exposure: Pipeline programs and future revenue potential
Recent and future financings, including PIPEs and ELOC usage, can expand share count materially.
Exposure: Existing common stockholders
Persistent losses and negative operating cash flow increase the risk of liquidity stress.
Exposure: Balance sheet and operating continuity
The company relies on licensed IP, advisors, and outside service providers to progress programs.
Exposure: Program continuity and deal terms
Accounting
Judgemental itemsThe company currently has no product sales, so future revenue will depend on licensing or commercialization terms.
Impact: Any future collaboration or license revenue may be recognized over time or at milestones depending on contract terms.
The company issued RSUs and equity-linked consideration to advisors and service providers.
Impact: Can materially increase G&A expense without cash outflow.
Placement agents received warrants and the company used PIPE/ELOC structures.
Impact: Affects dilution, financing expense, and potentially fair value measurements.
The company has recurring losses and depends on external capital.
Impact: Management judgment affects disclosures and assessment of funding sufficiency.
Similar listed companies
Publicly listed companies with a comparable business focus.
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Last updated: 24/09/2026